Santhosh Palani
CIK: 0002013475
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 17, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares- - May 18, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)Direct9.4K shares- - Mar 24, 2026PYXS
Pyxis Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
45.9K shares- - Jun 13, 2025ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares- - Mar 31, 2025PYXS
Pyxis Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
37K shares at avg. $0.98-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc. | Award(A) | 9,366 | - | $0 | Direct |
| Mar 24, 2026 |  PYXS Pyxis Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 45,867 | - | - | Direct |
| Jun 13, 2025 | ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| Mar 31, 2025 | PYXS Pyxis Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 36,979 | $0.98 | - | Direct |
1-5 of 5 transactions
About Palani Santhosh
Palani Santhosh (SEC CIK 0002013475) files insider reports with the SEC as Director of Acrivon Therapeutics, Inc. (ACRV) and Director of Pyxis Oncology, Inc. (PYXS).
Signal8 holds 5 ownership filings by Palani Santhosh, all Form 4s, filed between Apr 2, 2025 and Jun 22, 2026. Those filings report 5 transactions, from Mar 31, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Palani Santhosh's filings is in WATERTOWN, MA.
Recent filings by Palani Santhosh
- Jun 17, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
- May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
- Mar 24, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
- Jun 13, 2025: Grant or award of ACRV derivative securities (Form 4, code A).
- Mar 31, 2025: Grant or award of PYXS derivative securities (Form 4, code A).
Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)
- Miller Mary, Chief Legal Officer
- Levin Michaela, Chief Business Officer
- Blume-Jensen Peter, President and CEO
- Peterson Katharine, Chief Accounting Officer
- Gamelin Erick, Chief Development Officer
- Devroe Eric, Chief Operating Officer